Study Title and Description
Tamoxifen and mammographic breast densities.
Key Questions Addressed
|3||Key Question 3. What are the harms of using medications to reduce risk for primary breast cancer? Key Question 3a. Do harms of risk-reducing medications vary by timing of initiation and/or duration of use? Key Question 3b. Do harms of risk-reducing medications persist beyond discontinuation of use?|
Primary Publication Information
|Title||Tamoxifen and mammographic breast densities.|
|Author||Brisson J., Brisson B., Coté G., Maunsell E., Bérubé S., Robert J.|
|Country||Epidemiology Research Group, Saint-Sacrement Hospital CHA, Quebec City, Quebec, Canada.|
Pubmed ID: 11008908
Secondary Publication Information
There are currently no secondary publications defined for this study.
Extraction Form: Key Questions 1-4
Results & Comparisons
No Results found.